High-content fluorescent-based assay for screening activators of DNA damage checkpoint pathways

Journal of Biomolecular Screening

Volumn 13, Issue 6, 2008, Pages 538-543

  Zhang, Bin ^a   Gu, Xiubin ^b   Uppalapati, Uma ^b   Ashwell, Mark A ^b   Leggett, David S ^a   Li, Chiang J ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b ARQULE INC   (United States)

Author keywords

Chk2; Fold induction; High content analysis; KS score; Percentage of positively stained cells

Indexed keywords

CHECKPOINT KINASE 2; SMALL INTERFERING RNA;

ANALYTIC METHOD; ARTICLE; CELL ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; FLUORESCENCE ANALYSIS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION;

BIOLOGICAL ASSAY; CELL CYCLE PROTEINS; CELL DEATH; CELL LINE, TUMOR; COLORING AGENTS; DNA DAMAGE; ENZYME INDUCTION; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; FLUORESCENT DYES; HELA CELLS; HUMANS; INDOLES; PHOSPHORYLATION; PROPIDIUM; PROTEIN-SERINE-THREONINE KINASES; RNA, SMALL INTERFERING; TRANS-ACTIVATORS;

EID: 46149098086     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057108318509     Document Type: Article

References (15)

1. Collins I., Workman P: New approach to molecular cancer therapeutics. Nat Chem Biol 2006 ; 2: 689-700.
2. Workman P: Genomics and the second golden era of cancer drug development. Mol Biosyst 2005 ; 1: 17-26.
3. Workman P.: Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics. Cold Spring Harb Symp Quant Biol 2005 ; 70: 499-515.
4. Sancar A., Lindsey-Boltz LA, Unsal-Kacmaz K., Linn S.: Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rex Biochem 2004 ; 73: 39-85.
5. Bartkova J., Horejsi Z., Koed K., Kramer A., Totf F., Zieger K.,, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005 ; 434: 864-870.
6. Gorgoulis VG, Vassiliou LV, Karakaidos P., Zacharatos P., Kotsinas A., Liloglou T.,, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005 ; 434: 829-830.
7. Kastan MB, Bartek J.: Cell-cycle checkpoints and cancer. Nature 2004 ; 432: 316-323.
8. Bartek J., Lukas J.: Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003 ; 3: 421-429.
9. Chen CR, Wang W., Rogoff HA, Li X., Mang W., Li CJ: Dual induction of apoptosis and senescence in cancer cells by Chk2 activation: checkpoint activation as a strategy against cancer. Cancer Res 2005 ; 65: 6017-6021.
10. Li CJ: Therapeutic biology: checkpoint pathway activation therapy, HIV Tat, and transkingdom RNA interference. J Cell Physiol 2006 ; 209: 695-700.
11. Rausch O: High-content cellular screening. Curr Opin Chem Biol 2006 ; 10: 316-320.
12. Lee S., Howell BJ: High-content screening: emerging hardware and software technologies. Methods Enzymol 2006 ; 414: 468-483.
13. Haney SA, LaPan P., Pan J., Zhang J.: High-content screening moves to the front of the line. Drug Discov Today 2006 ; 11: 889-894.
14. Evans DM, Azorsa DO, Mousses S.: Genome scale cytometry: high-content analysis for high throughput RNAi phenotype profiling. Drug Discov Today Technol 2005 ; 2: 141-146.
15. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE,, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999 ; 286: 2528-2531.